表面修饰白蛋白纳米粒在肿瘤靶向治疗中的研究进展

摘要/Abstract

摘要：

目前临床肿瘤治疗中的药物多为非选择性药物，在抑制肿瘤细胞增殖的同时，也会对正常组织器官产生显著的毒副作用，因此提高药物的肿瘤选择性，减少其在非靶向部位的聚集是提高抗肿瘤药物疗效的关键。白蛋白纳米粒作为药物载体，具有突出的生物学特性，目前已被应用于各种靶向制剂。本文对白蛋白纳米粒在肿瘤中的聚集特性，以及其经精氨酸-甘氨酸-天冬氨酸短肽（RGD肽）、叶酸、单克隆抗体、透明质酸、转铁蛋白等靶向材料修饰后在肿瘤靶向治疗中的研究和临床应用做了最新的概述，旨在为开发安全、有效的肿瘤靶向制剂提供参考。

关键词: 白蛋白纳米粒, 靶向修饰, 肿瘤治疗, 应用

Abstract:

At present, most drugs for clinical cancer therapy are non-selective, with the inhibition of tumor cell proliferation, they also have significant side effects on normal tissues, thereby improving the tumor-selective capacity, reducing their gathering in non-targeted areas are the keys to enhance the effectiveness of anti-cancer drugs. As drug carriers, albumin nanoparticles exhibit various outstanding biological properties, and now have been used in targeted delivery systems. The paper reviews the albumin's tumor aggregation features, the latest researches in the targeted therapy of tumor and clinical applications when they are modified with RGD peptides, monoclonal antibodies, folic acid, hyaluronic acid, transferrin and other targeted material，in order to provide advices for developing safe and effective tumor targeting drugs.

Key words: albumin nanoparticles, targeted modification, tumor therapy, applications

中图分类号:

许丽华，徐肖阳，徐骏军，俞文英. 表面修饰白蛋白纳米粒在肿瘤靶向治疗中的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(8): 948-954.

XU Lihua, XU Xiaoyang, XU Junjun, YU Wenying. Research progress of surface modified albumin nanoparticles in tumor targeting therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 948-954.

参考文献

［1］Heinrich AK, Lucas H, Schindler L, et al. Improved tumor specific drug accumulation by polymer therapeutics with pH-sensitive drug release overcomes chemotherapy resistance［J］. Mol Cancer Ther, 2016, 15(5): 998-1007.
［2］Navai SA, Ahmed N. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells ［J］. Biochem Soc Trans, 2016, 44(2): 391-396.
［3］Ruttala HB, Ko YT. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy ［J］. Pharm Res, 2014, 32(3):1002-1016.
［4］Loureiro A, Azoia NG, Gomes AC, et al. Albumin-based nanodevices as drug carriers ［J］. Curr Pharm Des, 2016, 22(10): 1371-1390.
［5］Lohcharoenkal W, Wang L, Chen YC, et al. Protein nanoparticles as drug delivery carriers for cancer therapy ［J］. Biomed Res Int, 2014, 2014(1):180549.
［6］Battogtokh G, Kang JH, Ko YT. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug ［J］. Eur J Pharm Biopharm, 2015, 96: 96-105.
［7］Jacobs SA, Gibbs AC, Conk M, et al. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics［J］. Protein Eng Des Sel, 2015, 28(10):385-395.
［8］Kinoshita R, Ishima Y, Ikeda M, et al. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes ［J］. J Controlled Release, 2015, 217:1-9.
［9］Reddic RL, Zhang SH, Maeda N, et al. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression ［J］. Arterioscler Thromb, 1994, 14(1):141-147.
［10］Mocan L, Matea C, Tabaran FA, et al. Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus-ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor ［J］. Int J Nanomedicine, 2015, 2015(10): 5435-5445.
［11］Botos E, Klumperman J, Oorschot V, et al. Caveolin-1 is transported to multi-vesicular bodies after albumin-induced endocytosis of caveolae in HepG2 cells ［J］. J Cell Med, 2008, 12(5a): 1632-1639.
［12］Hoang B, Ernsting MJ, Roy A, et al. Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism ［J］. Biomaterials, 2015, 59: 66-76.
［13］Yin T, Cai H, Liu J, et al. Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel ［J］. Eur J Pharm Sci, 2015, 83: 79-87.
［14］柳莹, 武鑫, 刘皋林,等. 适配体修饰的纳米粒在肿瘤诊断与治疗中的应用［J］. 中国临床药理学与治疗学, 2016, 21(3): 341-346.
［15］Dingjan T, Spendlove I, Durrant LG, et al. Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies ［J］. Mol Immunol, 2015, 67(2 Pt A): 75-88.
［16］Guo Z, He B, Jin H, et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering ［J］. Biomaterials, 2014, 35(23): 6106-6017.
［17］Fiorini C, Cordani M, Padroni C, et al. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine ［J］. Biochim Biophys Acta, 2015, 1853(1): 89-100.
［18］Ji S, Xu J, Zhang B, et al . RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy ［J］. Cancer Biol Ther, 2012, 13(4): 206-215.
［19］Ming X, Carver K, Wu L. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides ［J］. Biomaterials, 2013, 34(32): 7939-7949.
［20］Bhunia SK, Maity AR, Nandi S, et al. Imaging cancer cells expressing the folate receptor with carbon dots produced from folic acid ［J］. Chembiochem, 2016, 17(7): 614-619.
［21］Shen Z, Li Y, Kohama K, et al. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres ［J］. Pharmacol Res, 2011, 63(1): 51-58.
［22］Qi L, Guo Y, Luan J, et al. Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor-targeting delivery system ［J］. J Mater Chem B, 2014, 2(47): 8361-8371.
［23］Feng L, Wang W, Yao HP, et al. Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases ［J］. Methods Mol Biol, 2015, 1233: 151-159.
［24］Fadaeian G, Shojaosadati SA, Kouchakzadeh H, et al. Targeted delivery of 5-fluorouracil with monoclonal antibody modified bovine serum albumin nanoparticles ［J］. Iran J Pharm Res, 2015, 14(2): 395-405.
［25］Hapuarachchige S, Zhu W, Kato Y, et al. Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics ［J］. Biomaterials, 2014, 35(7):2346-2354.
［26］Li W, Yi X, Liu X, et al. Hyaluronic acid ion pairing nanoparticles for targeted tumor therapy ［J］. J Control Release, 2016, 225: 170-182.
［27］Zhong Y, Zhang J, Cheng R, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts ［J］. J Control Release, 2015, 205:144-154.
［28］Pulakkat S, Balaji SA, Rangarajan A, et al. Surface engineered protein nanoparticles with hyaluronic acid based multilayers for targeted delivery of anticancer agents ［J］. ACS Appl Mater Interfaces, 2016, 8(36): 23437-23449.
［29］方奕巍, 尹宗宁. 透明质酸修饰的白蛋白纳米粒的制备及抗肿瘤作用的初步评价［J］. 四川大学学报医学版, 2011, 42(4): 480-484.
［30］Kolhatkar R, Lote A, Khambati H. Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors ［J］. Curr Drug Discov Technol, 2011, 8(3): 197-206.
［31］Wang X, Huang X, Yang Z, et al. Targeted delivery of tumor suppressor microrna-1 by transferrin- conjugated lipopolyplex nanoparticles to patient-derived glioblastoma stem cells ［J］. Curr Pharm Biotechnol, 2014, 15(9): 839-846.
［32］Bae S, Ma K, Kim TH, et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types ［J］. Biomaterials, 2012, 33(5): 1536-1546.
［33］Yan G, Wang J, Hu L, et al. Stepwise targeted drug delivery to liver cancer cells for enhanced therapeutic efficacy by galactose-grafted, ultra-pH-sensitive micelles ［J］. Acta Biomater, 2017, pii: S1742-7061(17)30031-4.
［34］Mehdizadeh M, Rouhani H, Sepehri N, et al. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy ［J］. Artif Cells Nanomed Biotechnol, 2016, 45(3): 1-10.
［35］Taheri A, Dinarvand R, Nouri FS, et al. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy ［J］. Int J Nanomedicine, 2011, 6(6): 1863-1874.
［36］Kesharwani P, Jain A, Jain A, et al. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumor ［J］. Rsc Adv, 2016, 6(92): 89040-89050.
［37］Byeon HJ, Le QT, Lee S, et al. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors ［J］. J Cont Rel, 2016, 225: 301-313.
［38］郝和群. 具有肿瘤靶向功能的阿霉素/白蛋白-葡聚糖纳米粒子［D］. 复旦大学, 2013.
［39］Qi WW, Yu HY, Guo J, et al. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy ［J］. Mol Pharm, 2015, 12(3): 675-683.
［40］Li C, Zhang D, Guo H, et al. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin ［J］. Int J Pharm, 2013, 448(1): 79-86.
［41］Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer ［J］. Ann Oncol, 2006, 17(8): 1263-1268.
［42］姬时宇, 胡毅. 白蛋白结合型紫杉醇治疗晚期原发性肝癌的效果观察［J］. 临床肝胆病杂志, 2016, 32(10): 1911-1915.
［43］Gonzalezangulo AM, Mericbernstam F, Chawla S, et al. Weekly nab-rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial ［J］. Clin Cancer Res, 2013, 19(19): 5474-5484.
［44］Ueno NT, Mamounas EP. Neoadjuvant nab-paclitaxel in the treatment of breast cancer ［J］. Breast Cancer Res Treat, 2016, 156(3): 427-440.
［45］Blair HA, Deeks ED. Albumin-bound paclitaxel: a review in non-small cell lung cancer ［J］. Drugs, 2015, 75(17): 2017-2024.
［46］John A. ABI-008 trial in patients with hormone-refractory prostate cancer. available at: https://clinicaltrials.gov/ct2/show/NCT00477529?term=ABI-008&rank=1.html ［EB/OL］.
［47］Nuhad KI. ABI-008 trial in patients with metastatic breast cancer. available at: https://clinicaltrials.gov/ct2/show/NCT00531271 term=ABI-008&rank=2.html ［EB/OL］.
［48］Ana M, Sant P. ABI-009 trial in patients with advanced non-hematologic malignancies. available at: https://clinicaltrials.gov/ct2/show/NCT00635284?term=ABI-009&rank=1.html ［EB/OL］.
［49］James MK. Phase 1/2 study of ABI-009 in nonmuscle invasive bladder cancer. available at: https://clinicaltrials.gov/ct2/show/NCT02009332?term=ABI-009&rank=3.html ［EB/OL］.
［50］Patricia ML, John S. A phase 1 trial of ABI-011 in patients with advanced solid tumors or lymphomas. available at: https://clinicaltrials.gov/ct2/show/NCT01163071?term=ABI-011& rank=2.html ［EB/OL］.

[1]	邵明坤, 刘蓉, 孙品, 关水, 廖炳灿, 李莎, 丛滔, 梁凯, 马辉, 孙长凯. 褪黑素人体网络机制及其临床应用[J]. 中国临床药理学与治疗学, 2022, 27(9): 1031-1040.
[2]	王金伙, 郭建荣. 阿芬太尼的临床药理特性及其麻醉应用进展[J]. 中国临床药理学与治疗学, 2021, 26(7): 824-829.
[3]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[4]	梁庆, 王晖. 氮酮与薄荷醇联用对5-氟尿嘧啶的促透作用[J]. 中国临床药理学与治疗学, 2020, 25(7): 734-739.
[5]	王玉珏, 尚新悦, 姚国栋. 芫花酯甲的药理作用与临床应用[J]. 中国临床药理学与治疗学, 2020, 25(10): 1188-1194.
[6]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[7]	魏兆明，江文胜，高艺，张娟娟. 脂肪间充质干细胞的生物学特性及潜在临床应用[J]. 中国临床药理学与治疗学, 2019, 24(1): 116-120.
[8]	赵小彬，余陈欢，夏爱晓，俞文英，俞冰. 纳米载体特异性靶向TAMs治疗肿瘤的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(7): 830-835.
[9]	刘晓萍，赖香茂，王海全，陈玉梅，张冬梅. 药物整合在慢性阻塞性肺疾病合并焦虑抑郁障碍患者中的应用价值[J]. 中国临床药理学与治疗学, 2016, 21(9): 1038-1041.
[10]	李曙，吴超，高红亮，贾金礼，虞乐，龙雪峰，张根葆，洪云. 蛇毒有效成分的药理研究进展及其临床应用[J]. 中国临床药理学与治疗学, 2016, 21(10): 1191-1195.
[11]	王福根, 梁伟峰, 席建军, 孙晶晶, 潘金明, 叶荣夏, 潘旭旺, 蔡兆斌. 非酒精性脂肪性肝炎动物模型的建立与应用[J]. 中国临床药理学与治疗学, 2015, 20(7): 835-840.
[12]	张雪, 吴兰香, 张陶蓝, 温纯洁, 付利娟, 周宏灏. β-异硫氰酸苯乙酯多靶向抗肿瘤作用机制研究进展[J]. 中国临床药理学与治疗学, 2015, 20(2): 217-222.
[13]	张哲, 孙立, 袁胜涛. 拓扑替康联合用药抗肿瘤研究进展[J]. 中国临床药理学与治疗学, 2015, 20(1): 106-111.
[14]	夏泉, 黄燕, 汪燕燕, 许杜娟, 胡乃中, 胡静, 梅俏, 陈飞虎. 巯嘌呤甲基转移酶基因多态性联合硫鸟嘌呤核苷酸血药浓度监测在硫唑嘌呤治疗炎症性肠病治疗中的临床应用[J]. 中国临床药理学与治疗学, 2014, 19(3): 302-308.
[15]	严尚学, 邓晓媚, 徐星铭, 魏伟. 对狼疮性肾炎治疗药物的临床合理应用新认识[J]. 中国临床药理学与治疗学, 2013, 18(5): 570-575.